Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial - Hasan, A; Roeh, A; Leucht, S (Contemp Clin Trials Commun, 2020)